Clinical Trial

A Study of LX107 Gene Therapy in AIPL1-IRD Patients

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-03; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Recruiting 2026-03-09
Trial Details
NCT Number NCT07063030
Lead Sponsor Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators: Innostellar Biotherapeutics Co.,Ltd
Conditions Retinal Dystrophy
Enrollment 13 participants
Start Date 2025-07-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10